AstraZeneca resumes Covid-19 vaccine trials in the UK

AstraZeneca resumes Covid-19 vaccine trials in the UK

While AstraZeneca resumes clinical trials in the United Kingdom, the Indian regulator has asked Serum Institute of India (SII) to suspend recruitments for phase-2 and 3 clinical trials of the Oxford-AstraZeneca vaccine candidate and has directed the firm to increase the safety monitoring of the subjects already vaccinated as part of the trial. The trial was resumed on Saturday with the approval of British regulators.

Last week, the company had paused global trials due to an adverse event reported in one patient in the UK.

Highlighting the importance of the three phases of vaccine trials, the physician said the drug manufacturing company, AstraZeneca, stopped its Oxford University randomised clinical trial when one of the participants developed an unexplained illness.

The statement said the UK Medicines Health Regulatory Authority approved trials to resume after an independent review of data "triggered a voluntary pause" on September 6. This pause shows we will always put safety first.

Participants in the third phase of Egypt's clinical trials for a coronavirus vaccine will not be paid, Minister of Health Hala Zayed said Sunday.

"The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume", AstraZeneca said. The company hopes that a vaccine would be ready by year-end or early 2021. This is the second known hold of studies of the AstraZeneca vaccine.

Michael Bloomberg to spend $136 million in Florida for Biden
He has largely been silent on the blazes, which Oregon's emergency management director said was a possible "mass fatality event". The tightening race in a number of the most contested states has led to a renewed effort for Trump to expand his electoral map.

The rebound of the tanker market is mostly dependent on the release of a vaccine to combat COVID-19, as this will prove to be the determining factor towards unlocking the global economy and with it, oil demand. "They have to be followed up for a certain length of time, a minimum of six months to be able to assess both on the protective efficacy and safety", she said, indicating that more details on the other Covid-19 vaccines in advanced trials would possibly be available by later this year or early next.

A Phase III trial is a large-scale one involving thousands of people - in Russian Federation, 40,000 - over a longer stretch of time.

Over 18,000 individuals globally have reportedly received study vaccines as part of the trial. The company in July had reported that the vaccine was demonstrating promising results and had produced strong immune response in the candidates who were administered this vaccine. The ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to grow in humans.

There are 176 coronavirus vaccines in the works.

India also has at least two frontrunner candidates in the global race for finding a vaccine against the coronavirus.

Related Articles